Vascular Biogenics (VBLT) Set to Announce Quarterly Earnings on Monday

Vascular Biogenics (NASDAQ:VBLT) will be issuing its quarterly earnings data before the market opens on Monday, May 14th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Vascular Biogenics (NASDAQ:VBLT) last announced its earnings results on Thursday, March 15th. The biopharmaceutical company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.05 by $0.19. The business had revenue of $13.86 million for the quarter. On average, analysts expect Vascular Biogenics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of VBLT stock opened at $2.15 on Friday. The firm has a market cap of $65.03 million, a PE ratio of -5.81 and a beta of -1.69. Vascular Biogenics has a 52 week low of $2.01 and a 52 week high of $9.05.

VBLT has been the topic of several research analyst reports. Zacks Investment Research cut Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Thursday, January 25th. HC Wainwright set a $3.00 target price on Vascular Biogenics and gave the stock a “hold” rating in a report on Thursday, March 22nd. ValuEngine cut Vascular Biogenics from a “sell” rating to a “strong sell” rating in a report on Friday, March 9th. Piper Jaffray cut Vascular Biogenics from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Thursday, March 8th. Finally, Chardan Capital cut Vascular Biogenics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $25.00 to $3.00 in a report on Thursday, March 8th. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $3.19.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Earnings History for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply